Passive Antibody Administration (Immediate Immunity) as a Specific Defense Against Biological Weapons

Casadevall, Arturo

Back to Previous Page

Passive Antibody Administration (Immediate Immunity) as a Specific Defense Against Biological Weapons

Published Date:

Aug 2002

Source:

Emerg Infect Dis. 8(8):833-841.

[PDF-288.17 KB]

Details:

Alternative Title:

Emerg Infect Dis

Personal Author:

Casadevall, Arturo

Description:

The potential threat of biological warfare with a specific agent is proportional to the susceptibility of the population to that agent. Preventing disease after exposure to a biological agent is partially a function of the immunity of the exposed individual. The only available countermeasure that can provide immediate immunity against a biological agent is passive antibody. Unlike vaccines, which require time to induce protective immunity and depend on the host's ability to mount an immune response, passive antibody can theoretically confer protection regardless of the immune status of the host. Passive antibody therapy has substantial advantages over antimicrobial agents and other measures for postexposure prophylaxis, including low toxicity and high specific activity. Specific antibodies are active against the major agents of bioterrorism, including anthrax, smallpox, botulinum toxin, tularemia, and plague. This article proposes a biological defense initiative based on developing, producing, and stockpiling specific antibody reagents that can be used to protect the population against biological warfare threats.

Subject:

[+]

Document Type:

Journal Article

Collection(s):

Emerging Infectious Diseases

Main Document Checksum:

[+]

File Type:

Supporting Files:

	01-0516_FinalP.nxml	text/plain
	license.txt	text/plain

No Related Documents.

The economic impact of a bioterrorist attack: are prevention and postattack intervention programs justifiable?

[PDF - 807.22 KB]

Personal Author:

Kaufmann, A. F. ; Meltzer, M. I. ; ...

Published Date:

1997 Apr-Jun

Source:

Emerg Infect Dis. 3(2):83-94.

Description:

Understanding and quantifying the impact of a bioterrorist attack are essential in developing public health preparedness for such an attack. We constr...

File Type:

[PDF - 807.22 KB]

File Type:

[PDF - 807.22 KB]
Meeting report : “Bacillus anthracis Bioterrorism Research Priorities for Public Health Response,” December 10-11, 2001, CDC, Atlanta, GA

[PDF - 468.34 KB]

Corporate Authors:

National Center for Infectious Diseases (U.S.) ; Centers for Disease Control and Prevention (U.S.) ;

Conference Authors:

Bacillus anthracis Bioterrorism Research Priorities for Public Health Response (2001 : Atlanta, GA)

Published Date:

7/24/02

Description:

This meeting provided a forum for 132 representatives from the Department of Health and Human Services (Centers for Disease Control and Prevention (CD...

File Type:

[PDF - 468.34 KB]

File Type:

[PDF - 468.34 KB]
Antimicrobial susceptibility of Bacillus anthracis isolates associated with intentional distribution in Florida, New Jersey, New York, Pennsylvania, Virginia, and Washington, D.C., September - October, 2001

[PDF - 563.76 KB]

Corporate Authors:

Centers for Disease Control and Prevention (U.S.)

Published Date:

10/22/01

Series:

HAN ; 041

Description:

Monday, October 22, 2001, 20:54 EDT (8:54 PM EDT)CDCHAN-00041-2001-10-22-ADV-NThe antimicrobial susceptibility patterns of eleven Bacillus anthracis i...

File Type:

[PDF - 563.76 KB]

File Type:

[PDF - 563.76 KB]
No Such Thing as Chronic Q Fever

[PDF - 303.12 KB]

Personal Author:

Million, Matthieu ; Raoult, Didier ;

Published Date:

May 2017

Source:

Emerg Infect Dis. 23(5):856-857.

Description:

Modern diagnostic methods enable clinicians to look beyond a diagnosis of chronic Q fever and discern whether patients instead have persistent focaliz...

File Type:

[PDF - 303.12 KB]

File Type:

[PDF - 303.12 KB]
Vaccines, pharmaceutical products, and bioterrorism: challenges for the U.S. Food and Drug Administration.

[PDF - 66.12 KB]

Personal Author:

Zoon, K. C.

Published Date:

1999 Jul-Aug

Source:

Emerg Infect Dis. 5(4):534-536.

File Type:

[PDF - 66.12 KB]

File Type:

[PDF - 66.12 KB]

Passive Antibody Administration (Immediate Immunity) as a Specific Defense Against Biological Weapons

Passive Antibody Administration (Immediate Immunity) as a Specific Defense Against Biological Weapons

You May Also Like:

Have Questions?

CDC INFORMATION

CONNECT WITH CDC